|
|
||||||||



,
,
* Graduate Program Immunology,
Graduate Program in Cellular and Molecular Biology,
Department of Medicine,
Department of Microbiology and Immunology, and
¶ Masters of Public Health Program, University of Michigan, Ann Arbor, MI 48109
| Abstract |
|---|
|
|
|---|
| Introduction |
|---|
|
|
|---|
MHC-I can also be recognized by MHC-I-specific inhibitory receptors, such as killer cell Ig-like receptors (KIR) (4). These receptors are classically thought to be expressed on NK cells to facilitate the eradication of virally infected or tumorigenic cells that have down-modulated MHC-I. More recently, evidence has been accumulating that these receptors are also up-regulated with the acquisition of cytotoxic function in CD8+ T cells (5). In this case they may serve as an important negative feedback mechanism that aids in the prevention of autologous damage by raising the threshold for cell lysis (5).
There are three major subtypes of classical MHC-I molecules that serve these roles. HLA-A, B, and C all have the capacity to present viral Ags to CTLs. Additionally, almost all HLA-C molecules are recognized by KIRs. Perhaps because of the crucial role of HLA-C as an inhibitory molecule capable of sending a dominant-negative signal (6), HLA-C is normally expressed at low levels at the cell surface. HLA-C H chain mRNA is unstable (7), the HLA-C H chain protein is not stably expressed at the cell surface, and it does not associate efficiently with the MHC-I L chain (β2-microglobulin) (8, 9, 10). Additionally, HLA-C presents a more restricted repertoire of peptides causing it to be retained in the endoplasmic reticulum (ER) in complex with the TAP, which is responsible for transporting peptides into the ER for MHC-I loading. The retained HLA-C is then eventually degraded in the ER (8). The addition of HLA-C-specific peptides has been shown to release HLA-C from TAP in vitro (8) and to increase the cell surface expression of HLA-C (11).
We examined the expression of HLA-Cw*0401 relative to HLA-A*0201 in a variety of cell types, including T cell lines, primary T cells, and monocytic cell lines and confirmed that HLA-Cw*0401 was poorly expressed on the cell surface relative to HLA-A*0201. To better understand the amino acid sequences governing HLA-C surface expression, we examined the intracellular trafficking of chimeric molecules that contained the HLA-A*0201 extracellular domain and the HLA-C cytoplasmic tail (A2/C) or the HLA-Cw*0401 extracellular domain and the HLA-A cytoplasmic tail (Cw4/A). Not surprisingly, the extracellular domain of HLA-C was responsible for promoting retention in the ER. Remarkably, however, the cytoplasmic tail also had an effect on cell surface expression by increasing internalization at the cell surface and targeting the molecules for degradation in acidic organelles. Mutagenesis studies revealed that aspartic acid at position 333, serine at position 335, and isoleucine at position 337 were key amino acids that affected the activity of this motif. Finally, we found that the complex regulation of HLA-C surface expression allowed the specific up-regulation of HLA-C upon differentiation of primary monocytes and monocytic cell lines into macrophage-like cells. The specific induction of HLA-C expression with differentiation strongly suggests that there is a unique role for HLA-C in APCs. We propose that inhibitory signals sent via HLA-C play a role in down-modulating the normal CD8+ cellular immune response and/or that it functions to specifically limit the lysis of APCs that are cross-presenting Ag.
| Materials and Methods |
|---|
|
|
|---|
MSCV 2.1 hemagglutinin (HA)-HLA-A*0201 was constructed as previously described (12). For MSCV 2.1 HA-HLA-Cw*0401, the HLA-Cw*0401 open reading frame (Peter Parham, Stanford University) was amplified with the following primers, 5'-CAATCTCCCCAGACGCCGAGATGCG-3' and 5'-CCGCTCGAGTCAGGCTTTACAAGCGATGAGAGA-3'. The PCR product was digested with NaeI and XhoI and the 3' fragment was gel purified. This fragment was then ligated to the 5' leader sequence plus the HA tag from HA-HLA-A*0201 (isolated by digesting MSCV 2.1 HA-HLA-A*0201 with EcoRI and NaeI) and MSCV 2.1 digested with EcoRI and XhoI.
MSCV 2.1 HA-Cw4/A2 was constructed by digesting MSCV 2.1 HA-HLA-Cw*0401 with EcoRI and XhoI, subcloning this fragment into the same sites in Litmus 29 to generate Litmus 29 HLA-Cw*0401. A three-way ligation was then performed with a EcoRI to SapI fragment from Litmus 29 HLA-Cw*0401 that encodes the extracellular domain of HLA-Cw*0401, a DNA fragment encoding the HLA-A*0201 cytoplasmic tail digested with Sap I and XhoI (generated by PCR amplification of MSCV 2.1 HA-HLA-A*0201 with the following primers 5'-GTGATCACTGGAGCTGTGGTCGCTGCT-3' and 5'-CCGCTCGAGTCACACTTTACAAGCTGTGAGAGACAC-3'), and MSCV 2.1 digested with XhoI and EcoRI.
MSCV A2/C was constructed by first PCR amplifying the Cw*0401 cytoplasmic tail using the following primers 5'-CAGGTGACCGGTGCTGTGGTCGCTGCTGTGATGTGGAGGAGGAAGAGCTCAGGTGGA-3' and 5'-CACCTGCAGCTGTCAGGCTTTACAAGCGATGAG-3' and then digesting with AgeI. This fragment was then ligated into pcDNA3.1 HLA-A*0201 AgeI (a plasmid containing an HLA-A*0201 open reading frame with a silent sequence change to introduce an AgeI site (13)) digested with AgeI and EcoRV to generate pcDNA3.1 A2/Cw4. A DNA fragment encoding part of the HLA-A*0201 extracellular domain and the HLA-Cw*0401 cytoplasmic tail was isolated by digesting pcDNA3.1 A2/Cw4 with PmlI and EcoRV. This fragment was then ligated into MSCV2.1 HA-HLA-A*0201 digested with PmlI and HpaI.
pcDNA3.1(+) internal ribosome entry site (IRES) GFP was generated by isolating the IRES GFP cassette from MSCV IRES GFP (14) digested with XhoI and SalI. This cassette was then ligated into pcDNA3.1(+) digested with XhoI. pcDNA3.1(+) HA-HLA-A*0201 IRES GFP and pcDNA3.1(+) HA-HLA-Cw*0401 were generated by isolating HA-HLA-A*0201 or HA-HLA-Cw*0401 from MSCV 2.1 HA-HLA-A*0201 or MSCV2.1 HA-HLA-Cw*0401 as follows: MSCV 2.1 HA-HLA-A*0201 or MSCV 2.1 HA-HLA-Cw*0401 were digested with EcoRI, filled in using Klenow, and then digested with XhoI. These fragments were then ligated into pcDNA3.1(+) IRES GFP digested with EcoRV and XhoI.
The MSCV 2.1 HA-A2/Cw4 point mutations N327D, E334V, I337T, D333A, SSAA, S335E, and MSCV 2.1 HA-A*0201 T337I were introduced using PCR. The 5' primer for all the constructs was 5'-CGACCGCCTCGATCCTCC-3'. The 3' primers used are as follows: N327D 5'-CCGCTCGAGTCAGGCTTACAAGCGATGAGAGACTCATCAGAGCCCTGGGC ACTGTCGCTGGACGC-3', E334V 5'-CCGCTCGAGTCAGGCTTTACAAGCGATGAGAGATACATCAGAGCCCTG-3', I337T 5'-CGGCTCGAGCTGTCAGGCTTTACAAGCTGTGAGAGACTC-3', D333A 5'-GCCCTCGAGTCAGGCTTTACAAGCGATGAGAGACTCTGCAGAGCCCTGGGCACTGTTGCTGGA-3', SSAA 5'-CCGCTCGAGCGGTCAGGCTTTACAAGCGATGAGTGCCTCATCTGCGCC-3' and S335E 5'-CCGCTCGAGCGGTCAGGCTTTACAAGCGATGAGCTCCTCATCAGA-3'. The template for all the PCR was MSCV 2.1 HA-A2/Cw4. The resulting PCR product was digested with EcoRI and XhoI and ligated into MSCV 2.1 digested with the same enzymes. The C320Y point mutation was generated using a two-round PCR mutagenesis approach. The first-round PCR consisted of two reactions; reaction 1 contained the primers 5'-CGACCGCCTCGATCCTCC-3' and 5'-AGCCTGAGAGTAGCTCCCTCC-3', and reaction 2 contained the primers 5'-GGAGGGAGCTACTCTCAGGCT-3' and 5'-CCGCTCGAGTCAGGGTTTACAAGCGATGAGAGA-3'. The template for both reactions was MSCV 2.1 HA-A2/Cw4. The second-round PCR contained primers 5'-CGACCGCCTCGATCCTCC-3' and 5'- CCGCTCGAGTCAGGGTTTACAAGCGATGAGAGA-3'. The template for this reaction was 1 µl from each of the one-round PCR. The resulting PCR product was digested with EcoRI and XhoI and ligated into MSCV 2.1 digested with the same enzymes.
Cell lines
THP-1 and U937 macrophage cell lines were obtained from the American Type Culture Collection. THP-1 cells were cultured in RPMI 1640 supplemented with 2 mM L-glutamine, 10 mM HEPES, 1 mM sodium pyruvate, 4.5 g/L glucose, 1.5 g/L sodium bicarbonate, 10% FBS, 0.05 mM 2-ME, and 2 mM penicillin, streptomycin, and glutamine. U937 and CEM cells were cultured with RPMI 1640 supplemented with 10% FBS, 10 mM HEPES, and 2 mM penicillin, streptomycin, and glutamine (R10). Cell lines expressing various MHC-I molecules were generated using murine retroviral vectors as previously described (14, 15) except that they were pseudotyped with pCMV VSV-G (Dr. Nancy Hopkins, Massachusetts Institute of Technology). Cells (1 x 106) were spin infected with the retroviral supernatants by centrifuging at 2500 rpm in a table top centrifuge for 2 h with 8 µg/ml polybrene. The cells were then selected with neomycin (1 mg/ml).
PBMC isolation and electroporation
PBMCs were isolated from buffy coats provided by the Lansing Red Cross by Ficoll-Hypaque centrifugation. Following isolation they were stimulated with 10 µg/ml PHA (Sigma-Aldrich); 24 h later IL-2 was added at 50 U/ml, and fresh IL-2 was added after 3 days. Five days after isolation, 5 x 106 stimulated PBMCs were electroporated using the Amaxa Nucleofector system. Electroporations were performed according to the manufacturers protocol, except following electroporation, the cells were placed in 500 µl of medium in 1.5 ml Eppendorf tubes and incubated for 10 min at 37°C before being placed in a 12-well dish.
Macrophage differentiation
Buffy coats provided by the New York Blood Center were purified by Ficoll-Hypaque centrifugation, and CD14+ mononuclear cells were isolated using the EasySep human CD14-positive selection kit (StemCell Technologies). Purity of the sorted CD14-positive cells was assessed by flow cytometry using FITC-conjugated mouse anti-human CD14 Ab (clone M5E2; BD Pharmingen). To assess MHC-I expression levels, freshly purified, undifferentiated cells were preincubated with 10% Fc block (Accurate Chemical & Scientific) in FACS buffer (10 mM HEPES, 2% FBS, 1% human serum, 0.02% azide) for 20 min on ice and then stained with Abs directed against HLA-A2 (BB7.2), HLA-C (L31; gift of Patrizio Giacomini, Regina Elena Cancer Institute, Italy), Bw4 (One Lambda), and Bw6 (One Lambda), depending on the donors MHC-I phenotype. The cells were also stained with matched, isotype control Abs (protein A purified IgG2b for BB7.2, IgG1 ascites for L31, and IgM for anti-Bw4 and anti-Bw6). For staining with L31, a citrate-phosphate buffer (pH 3.0) was used to release β2-microglobulin and expose the epitope as described previously (16, 17). To induce maturation, the CD14+ cells were plated at 1 x 106/ml in R10 plus GM-CSF for 5 days. The cells were then harvested and stained again with anti-MHC-I Abs as described above.
For differentiation of monocytic cell lines, one million THP-1 or U937 cells were treated with LPS (100 ng/ml for THP-1 and 10 ng/ml for U937) solubilized in DMSO in 1 ml of medium in a 24-well plate. Twenty four hours later, an additional 1 ml of medium was added containing PMA (200 ng/ml for THP-1 and 10 ng/ml for U937) and LPS. After 72 h at 37°C, cells were harvested by treatment with cell dissociation solution (Sigma-Aldrich) for 20 min at 37°C.
Western blot analysis
Cells were lysed in PBS, 0.3% CHAPS, 0.1% SDS (pH 8), and 1 mM PMSF. They were then normalized for total protein and separated by SDS-PAGE. Western blot analysis was performed with the following Abs: HA (HA.11, 1:5,000; Covance Research Products), and rat anti-mouse-HRP (1:25,000; Zymed Laboratories).
Immunofluorescence microscopy
CEM T cells were prepared for immunofluorescence microscopy as previously described (12) except that they were permeabilized with 0.1% digitonin (Wako Chemicals) diluted in Dulbeccos PBS with calcium and magnesium and blocked with equal parts wash buffer and Fc receptor blocker (Accurate Chemical & Scientific). To identify cell surface staining (Fig. 1G), ConA conjugated to AlexaFluor 488 (Molecular Probes) was diluted to 40 µg/ml and incubated with cells for 5 min on ice. To identify acidic compartments (Fig. 4C), CEM cells were pretreated with 100 nm bafilomycin A or DMSO for 4 h at 37°C. Following treatment, CEM cells were adhered to glass slides, fixed, permeabilized, and stained for indirect immunofluorescence as previously described (12). MHC-I was visualized using BB7.2 (1:100), and AlexaFluor 488 goat anti-mouse IgG2b (1:250; Invitrogen). LAMP-1 was visualized using a anti-LAMP-1 Ab (clone H4A3, 1:500; BD Pharmingen) and AlexaFluor 546 goat anti-mouse IgG1 (1:250; Invitrogen). For identification of the ER (Fig. 2C), HA-tagged molecules and KDEL were stained using mouse mAbs (HA.11, 1:50 and anti-KDEL, 1:200 (Stressgen)) followed by staining with appropriate secondary Abs (goat anti-mouse IgG1 AlexaFluor 488, and goat anti-mouse IgG2a AlexaFluor 546, 1:250; Molecular Probes). Images were collected using a Zeiss LSM 510 confocal microscope and processed with Adobe Photoshop software.
|
|
|
Microscopy images were quantified independently by two individuals who assessed the relative amount of colocalization and assigned a colocalization score between 0 and 3, where 3 was the maximal possible colocalization. For each condition, the samples were averaged and the percentage of maximum colocalization was determined by dividing each score by the highest score achieved.
Flow cytometry
Stains were performed as previously described (18) using an anti-HA Ab (HA.11, 1:50) or an anti-HLA-A2 Ab (BB7.2) (19) and goat-anti-mouse-PE (1:250; Biosource or Invitrogen). FACS analysis of the THP-1 and U937 cells was the same except the cells were incubated with Fc receptor blocker (Accurate Chemical & Scientific) for 20 min at 4°C before the anti-HA Ab incubation.
Transport, internalization, and metabolic labeling assays
The transport and endocytosis assays were performed essentially as previously described (20) except that an Ab directed against the HA tag (HA.11) was used. For metabolic labeling of total protein, fifteen million CEM T cells were pulse-labeled for 15 min with [35S]methionine and cysteine. For inhibitor studies, one third of the sample was harvested after the pulse while the remaining cells were then chased for 12 h in either RPMI 1640 with DMSO or 100 nM bafilomycin A (Sigma-Aldrich). Lysates were generated in PBS, 0.3% CHAPS, 0.1% SDS (pH 8), 1 mM PMSF, and precleared overnight. They were immunoprecipitated for 2 h with an Ab against HA (HA.11) and washed three times in radioimmunoprecipitation assay (RIPA) buffer (50 mM Tris (pH 8), 150 mM NaCl, 1% Nonidet P-40, 0.5% deoxycholate, 0.1% SDS). The immunoprecipitates were then eluted by boiling in 10% SDS, re-precipitated with an Ab against HA, and washed three times in RIPA buffer. The final immunoprecipitates were then separated by SDS-PAGE.
For metabolic labeling of phosphorylated protein, five million CEM T cells were labeled for 4 h with 0.5 mCi/ml [32P]orthophosphate in phosphate-free medium (RPMI 1640; Specialty Media) supplemented with 10% dialyzed FBS (Invitrogen). The cells were lysed with Nonidet P-40 lysis buffer (1% Nonidet P-40, 0.15 M NaCl, 0.01 M sodium phosphate, 2 mM EDTA, 50 mM sodium fluoride, 0.2 mM sodium vanadate, and 1 mM PMSF) and precleared overnight. They were immunoprecipitated with BB7.2 Ab for 2 h and washed three times in RIPA buffer (50 mM Tris (pH 8), 150 mM NaCl, 1% Nonidet P-40, 0.5% deoxycholate, 0.1% SDS). The immunoprecipitates were then separated by SDS-PAGE and the dried gel was exposed to a phosphor imager screen and analyzed on a Typhoon Trio PhosphorImager (GE Healthcare). Where indicated, cells were treated with 100 nM bafilomycin A or DMSO solvent control for 18–24 h.
Recycling assays
A measurement of the rate of recycling of internalized molecules was performed as described previously (21), except that washes were performed at room temperature to avoid inhibiting recycling with cold temperature (22). Briefly, cells were incubated with 150 µg/ml cycloheximide (Sigma-Aldrich) for 2–3 h in RPMI 1640 plus 10% serum. Then cells were harvested and an aliquot was removed and placed on ice. The remainder of the samples was stripped of stainable HLA-A2 by washing in 50 mM glycine, 100 mM NaCl (pH 3.4), twice, at room temperature for 1 min. The stripped cells were then washed in PBS and incubated at 37°C, 5% CO2 in medium without serum for the indicated period of time, in the presence of 150 µg/ml cycloheximide. (Samples were incubated without serum to avoid substitution of bovine β2-microglobulin present in serum for the human β2-microglobulin removed with the stripping protocol.) Cells were then placed on ice and stained for HLA-A2 with BB7.2, using wash buffers that included BSA instead of serum.
| Results |
|---|
|
|
|---|
To determine which amino acid differences played a role in reducing HLA-C surface expression, we first developed a way to clearly compare expression of these molecules. This was accomplished by attaching an HA tag to the N terminus of HLA-A*0201 and HLA-Cw4*0401 (HA-A2 and HA-Cw4; Fig. 1B). The HA tag, which was inserted just after the leader cleavage site, allowed us to compare the expression of heterologous proteins using the same Ab so that differences in Ab affinity did not confound our results. In prior publications, we have demonstrated that the presence of this tag does not affect the maturation and expression of HLA-A2 (12). Additionally, we have demonstrated that this tag does not affect recognition by the conformationally sensitive anti-HLA-A2 Ab, BB7.2 (12, 19).
We also made chimeric molecules in which the cytoplasmic tail domains of HLA-A or HLA-C were fused to the transmembrane domain of HA-Cw4 and HA-A2 to create HA-Cw4/A and HA-A2/C, respectively (Fig. 1B). DNAs encoding each of these proteins were cloned into murine retroviral vectors, and viral supernatants were used to transduce CEM T cells at a low multiplicity of infection to limit the number of transductants with multiple integrated copies. Bulk cell lines were then grown in selective medium to obtain a uniform population. To ensure that our results were not influenced by arbitrary variations introduced by individual transfections or transductions, the cell lines used in our investigations were re-made with new transfections and transductions on three separate occasions and in each case yielded similar relative expression levels.
Because, the translation initiation and leader sequences were the same for each molecule, we were able to measure initial protein synthesis as an estimate of the amount of translatable RNA in the cell. As shown in Fig. 1C (and quantified in Fig. 1D), the expression level of HA-A2 and HA-A2/C was not significantly different (p = 0.12). Despite this, we found that there was
3-fold less HA-A2/C on the cell surface (mean fluorescence intensity (MFI) = 50 ± 4 for HA-A2/C, compared with 149 ± 18 for HA-A2) (Fig. 1E). This was not an artifact of the presence of the HA tag, as independently constructed and expressed HLA-A2 and A2/C that lacked the tag behaved similarly when stained with the HLA-A2-specific mAb, BB7.2 (Fig. 1F). In addition, these data were corroborated by confocal microscopy (Fig. 1, G and H), which confirmed that HA-A2 was largely expressed on the cell surface, where it colocalized significantly with ConA. In comparison, HA-A2/C had a staining pattern that was distinctly different relative to that of ConA (Fig. 1G, compare panels 3 and 7, and quantification shown in Fig. 1H).
We also found that molecules with an HLA-C extracellular domain were expressed poorly on the cell surface relative to those containing HLA-A extracellular domains (MFI = 12 ± 3 for HA-Cw4 and 20 ± 2 for HA-Cw4/A2) (Fig. 1E). Given that we noted a slightly lower level of initial protein synthesis for these molecules relative to HLA-A2 (Fig. 1, C and D), we also verified these results in a different system that could better account for potential differences in gene copy number. In this case, HA-A2 and HA-Cw4 were cloned into a different vector, which allowed expression of both MHC-I and GFP from the same RNA molecule via an IRES element. Thus, this vector system allowed us to monitor the relative number of gene copies present in the cell by measuring GFP expression by FACS. These constructs were directly transfected into activated primary T cells and the surface expression levels of HA-A2 and HA-Cw4 in primary T cells expressing equivalent amounts of GFP was measured and compared with what was observed in CEM T cells. As shown in Fig. 1I, at similar GFP expression levels, the cell surface expression of HA-A2 and HA-Cw4 was comparable to that achieved in stable CEM T cell lines stained in parallel (Fig. 1I, right panels). Moreover, as shown in Fig. 1I, the pattern we observed was not changed by adding twice as much DNA to the transfection, indicating that, the surface expression of HA-Cw4 and HA-A2 was not substantially affected by differences in transfection conditions.
The HLA-C cytoplasmic tail contains an internalization and lysosomal trafficking signal
To determine how the cytoplasmic tail affected cell surface expression, we used pulse-chase labeling with endoglycosidase H (endo H) digestion to measure the rate at which molecules harboring this domain were transported into the Golgi apparatus where they become modified such that they were resistant to endo H digestion. We observed that the cytoplasmic tail did not influence the rate molecules acquired resistance to digestion by endo H (Fig. 2, A and B). In contrast, we confirmed prior indications that the extracellular domain of HLA-C promoted ER retention and degradation (Fig. 2A). These data were confirmed by confocal microscopy in which molecules containing the HLA-C extracellular domain colocalized with KDEL, a marker of the ER compartment (Fig. 2, C and D).
We then used pulse-labeling followed by a chase period in the presence of a cell impermeable biotinylation reagent, to determine the rate at which these molecules arrived at the cell surface. In these assays, the cell lysates were first immunoprecipitated with anti-HA. Then, one third of the cell lysates was analyzed directly (total), and the remaining two thirds was eluted from the beads and re-precipitated with avidin-agarose to isolate the subset of MHC-I at the cell surface (Fig. 3, A and B). As determined by phosphor imager analysis, we found that HA-A2/C was transported to the cell surface
2-fold more slowly than HA-A2 (p < 0.01, n = 2).
|
3- to 6-fold (Fig. 3D). We also examined whether HLA-A2 and A2/C differed with respect to how rapidly they were recycled to the cell surface following internalization. As shown in Fig. 3E, we did not detect any significant differences in recycling of HA-A2/C relative to HLA-A2 that would explain its lower expression levels. In fact, a slightly higher percentage of HA-A2/C was recycled to the cell surface from internal compartments (p = 0.036, n = 3).
We then examined the ultimate fate of HA-A2/C with longer pulse-chase experiments to determine whether it was targeted to lysosomal compartments after internalization. As shown in Fig. 4A and quantified in Fig. 4B, we found that mature, endo H resistant HA-A2/C was degraded approximately twice as fast as HA-A2. (HA-A2 had a half-life of 10.5 h, compared with 6 h for HA-A2/C). These data were confirmed by confocal microscopy in which we noted that HA-A2/C displayed extensive colocalization with LAMP-1, a marker of lysosomal organelles, when degradation was inhibited by bafilomycin, an inhibitor of the vacuolar ATPase that is required for efficient acidification and degradation in lysosomal compartments (Fig. 4C and quantified in Fig. 4D).
Finally, to provide further evidence that the degradation of HA-A2/C occurred in acidic compartments, such as lysosomes, we treated CEM T cells with bafilomycin to determine whether it reversed the degradation observed by pulse-chase analysis. As shown in Fig. 4E and quantified in Fig. 4F, bafilomycin treatment resulted in a 6-fold increase of HA-A2/C compared with a 2.2-fold increase for HA-A2 (p = 0.015, n = 3). In sum, these data suggest that the HLA-C cytoplasmic tail contains an internalization and lysosomal targeting signal.
Identification of a trafficking signal in the HLA-C cytoplasmic tail that promotes intracellular localization and lysosomal targeting
To determine which amino acids were responsible for the effects of the HLA-C tail, we focused on four amino acid differences between HLA-C and HLA-A/B molecules (Fig. 1A). Each of these amino acids was mutated in HA-A2/C, and stable CEM T cell lines were made as described above for HA-A2/C. Initial protein synthesis measurements indicated that the expression of each of these molecules was not significantly different from that of HA-A2/C, except for HA-A2/C D333A, which was expressed slightly less (p = 0.04, Fig. 5, A and B).
|
An analysis of intracellular transport, using the assay described above, revealed that HA-A2/C I337T transport was reduced compared with wild type HA-A2 (p < 0.001, n = 3), but was not significantly different from A2/C (Fig. 5E). Whereas, the flow cytometric internalization assay (described above) revealed that substitution of I337 reduced the internalization rate 15-fold (from 3.73% per minute to 0.25% per minute p < 0.01, Fig. 5F).
Finally, we used pulse-chase analysis plus or minus bafilomycin to measure the degree to which wild type and mutant molecules were degraded in acidic compartments. As shown in Fig. 5G and quantified in Fig. 5H, substitution of I337 in HA-A2/C increased the amount of recovered protein 4-fold in the control, DMSO treated, sample (compare lanes 5 and 8 in Fig. 5G, and quantification in Fig. 5H, p < 0.01), resulting in expression that was similar to that of HA-A2 (compare lanes 3 and 8 in Fig. 5E). Thus, I337 is a determinant required for accelerated internalization and degradation of molecules containing an HLA-C cytoplasmic tail domain.
To further define the internalization and lysosomal targeting motif in HLA-C, the highly conserved aspartic acid (D) at position 333 was changed to an alanine. Based on initial protein synthesis, this mutant was expressed slightly less than HA-A2/C (Fig. 5, A and B, p = 0.04), but its expression was not significantly different from HLA-A2 and most A2/C mutants (C320Y, N327D, I337T, T337I; Fig. 5, A and B). Substitution of D333 resulted in a substantial loss of cell surface expression compared with HA-A2/C, HA-A2 and the other HA-2/C mutants (Fig. 5, C and D, p values ranged from <1 x 10–4–10–6). The intracellular transport rate was not the explanation for the reduction in surface expression as this was similar to HA-A2/C (Fig. 6A). However, we found that substitution of D333 resulted in a 2-fold increase in internalization rate compared with HA-A2/C (p < 1 x 10–4) and a 5-fold increase relative to wild type HA-A2 (p < 1 x 10–4, Fig. 6B). Additionally, pulse-chase analysis revealed that mutation of D333 also caused an increase in turnover of mature, endo H-resistant molecules (Fig. 6, C and D). In sum, these data indicate that D333 functions to attenuate the downstream dihydrophobic internalization and lysosomal targeting signal.
|
The data we have acquired indicates that there are multiple mechanisms by which cells precisely regulate HLA-C expression. The extracellular domain promotes retention and degradation in the ER and the cytoplasmic domain promotes a limited amount of internalization and degradation. Thus, it seems that complex mechanisms exist to maintain significant intracellular levels of HLA-C while limiting (but not eliminating) surface expression. It makes sense that a molecule capable of sending a dominant inhibitory signal to killer T cells should be tightly regulated, as high expression could result in higher activation thresholds for the detection of virally infected or tumorigenic cells. However, the fact that intracellular pools of HLA-C are maintained suggests that there may be conditions in which it is advantageous to rapidly up-regulate HLA-C cell surface expression. We were unable to specifically induce HLA-C surface expression in T cells with a variety of stimuli, such as IFNs
and
or with compounds that stimulate T cells, such as IL-2 and PHA. Additionally, we were unable to up-regulate HLA-C expression by treatment of T cells with specific pathogens, such as HIV and adenovirus (data not shown).
It remained possible, however, that HLA-C had evolved to present peptides from certain types of pathogens, or that it functioned to inhibit killing under some conditions. For example, when APCs activate naive CTLs by cross-presenting exogenous Ag, it would not be advantageous to lyse the uninfected, cross-presenting APC. Thus it would make sense for these cells to up-regulate molecules that would send inhibitory signals to effector T cells that might otherwise mistake the APC for an infected target cell and lyse it. Indeed, it has recently been reported that coincident with acquisition of killer T cell effector functions, CTLs up-regulate the KIR family of inhibitory receptors (5).
To examine this possibility further, we isolated primary human CD14+ mononuclear cells from a normal, healthy donors peripheral blood. Some of the cells were stained immediately for HLA-C and HLA-B allotypes and the remainder was incubated in GM-CSF for five days to induce macrophage differentiation. To measure HLA-C surface expression, we obtained an Ab that specifically recognizes most HLA-C allotypes, (17, 25). As shown in Fig. 7A, left panel, HLA-C staining, as measured with the L31 Ab, was low in freshly isolated, undifferentiated CD14+ (
2.8-fold above background and more than 40-fold less than Bw6). After 5 days of culture in GM-CSF, HLA-C surface expression was dramatically up-regulated more than 20-fold relative to Bw6.
|
In undifferentiated nonadherent solvent (DMSO)-treated cells, HA-A2, HA-A2/C and HA-Cw4 were expressed in a manner that was very similar to what we observed in primary T cells and stable CEM T cell lines (Fig. 7B, panels 1 and 3). HA-A2 was expressed at comparably high levels and was largely endo H resistant (Fig. 7C, lanes 2 and 6), whereas HA-Cw4 was expressed at very low levels at the cell surface (Fig. 7B, panels 1 and 3) and was largely endo H sensitive (Fig. 7C, lanes 18 and 22). HA-A2/C was expressed at intermediate levels (Fig. 7B, panels 1 and 3) and had reduced amounts of endo H-resistant material relative to HLA-A2 (Fig. 7C, lane 10 and 14), presumably due to increased internalization and degradation in acidic compartments as was observed in other cell types (Figs. 3 and 4). B*4405 was expressed well on the cell surface (Fig. 7B, panels 5 and 7) and was largely endo H resistant (Fig. 7C, lanes 34 and 38), whereas B*4402 was expressed comparatively less well on the cell surface (Fig. 7B, panels 5 and 7) and was largely endo H sensitive due to ER retention (Fig. 7C, lanes 26 and 30; see also Ref. 26).
When U937 and THP-1 cell lines were treated with LPS and PMA to induce differentiation into macrophage-like cells, we observed no change in the surface expression of HA-A2 or HA-B*4402, and we noted a small decrease in the surface expression of HA-B*4405 (Fig. 7B). In contrast, we observed that A2/C cell surface expression was increased to achieve levels that were similar to wild-type HA-A2 (Fig. 7B, compare panels 1 and 2 or 3 and 4). Additionally, as shown in Fig. 7A, we also observed an increase in full-length HA-Cw4 cell surface expression.
The increase in surface expression of A2/C was reflected by an increase in the amount of endo H-resistant protein detected by Western blot analysis (Fig. 7C, compare lanes 10 and 12 for U937 cells or lanes 14 and 16 for THP-1 cells). We also noted an increase in the ratio of endo H resistant: sensitive forms of full length HLA-Cw*0401 (Fig. 7C, compare lanes 18 and 20 for U937 or lanes 22 and 24 for THP-1). Albeit, most of the full-length HLA-C molecules remained endo H sensitive.
The relative amount of endo H-resistant material for HA-A2 and HA-B*4405 remained unchanged. However, we did note an increase in the fraction of HA-B*4402 that became resistant to endo H (Fig. 7C, compare lanes 26 and 28 or 30 and 32). Thus, macrophage differentiation resulted in a complex set of effects that enhanced ER exit of some MHC-I molecules, like B*4402, that are normally retained in the ER because of problems with protein loading (26). In addition, macrophage differentiation increased the amount of endo H-resistant HA-A2/C, which is normally low because of lysosomal targeting of mature molecules.
To better understand the striking up-regulation of surface HA-A2/C and the stabilization of mature, endo H-resistant forms of A2/C in differentiated macrophage-like cells, we first examined internalization rate. As shown in Fig. 7D, we found that HA-A2/C was internalized 3.6 times more rapidly than HA-A2 in DMSO treated monocytic cells. However, after treatment with LPS and PMA, HA-A2 and HA-A2/C were internalized at very similar rates, suggesting that the activity of the cytoplasmic tail signal was modified with differentiation.
Evidence that HLA-C cell surface expression in macrophages is regulated by phosphorylation
The HLA-C internalization and lysosomal targeting signal is surrounded by serine residues (SDXSLI) and thus could be regulated by phosphorylation (27, 28). To examine this, we mutated these serine residues to alanine to prevent phosphorylation (A2/C SSAA). These constructs were expressed in both CEM cells and in U937 cells as described above. Then, phosphorylation of HA-A2, HA-A2/C and the mutant A2/C SSAA was directly assessed by labeling the cells with 32P orthophosphate and immunoprecipitating each molecule with the HLA-A2-specific Ab, BB7.2. As shown in Fig. 8, A and B, we readily detected phosphorylation of HLA-A2 (Fig. 8, A and B, lane 2). However, A2/C was expressed at reduced levels (Fig. 8, A, lane 10 and B, lane 9) and clear detection of phosphorylated A2/C required stabilization of the degraded molecules with the lysosomal inhibitor, bafilomycin (Fig. 8, A and B, compare lanes 3 and 4). Mutation of serine residues 332 and 335 stabilized A2/C protein (Fig. 8B, compare lanes 9 and 11) and dramatically reduced recovery of phosphorylated molecules (Fig. 8, A lane 8; B, lane 5). Thus, serines 332 and 335 were clearly necessary for both degradation and phosphorylation of the HLA-C cytoplasmic tail.
|
|
Following treatment with LPS and PMA to induce macrophage differentiation, we observed a 4-fold increase in HA-A2/C protein at the 12 h chase point compared with DMSO-treated cells (compare lanes 17 and 18 with lanes 23 and 24 in Fig. 9C). Mimicking phosphorylation at position 335 (S335E) prevented differentiation-induced stabilization of HA-A2/C (compare lanes 23 and 24 with lanes 47 and 48 in Fig. 9C). Conversely, inhibiting phosphorylation by substituting alanine at the same position maintained protein stability under all conditions (Fig. 9C, lanes 35–38). In sum, these data strongly indicate that phosphorylation of S335 in the HLA-C tail is necessary for lysosomal targeting and that macrophage differentiation inhibits phosphorylation of this residue.
To examine the effect of mimicking or inhibiting phosphorylation on internalization rate, we used the flow cytometric internalization assay described above. As shown in Fig. 9E (left graph), mimicking phosphorylation (S335E) accelerated internalization 1.7-fold (p < 0.01), whereas preventing phosphorylation at this position (SSAA) inhibited it 2.0-fold (p < 0.01). Following treatment with LPS and PMA, we again observed a decrease in the internalization rate of HA-A2/C (Fig. 9E, right graph). However, the phosphorylation mimic (S335E) did not respond, and continued to be internalized at a rapid rate. These data further support the model that phosphorylation is necessary for the internalization and degradation of HLA-C, and that macrophage differentiation resulted in hypophosphorylation, and increased expression of HLA-C.
Finally, to directly demonstrate that phosphorylation of A2/C is reduced upon macrophage differentiation, phosphorylation of HA-A2 and HA-A2/C was directly assessed by labeling the cells with 32P orthophosphate and each molecule was immunoprecipitated with the HLA-A2-specific Ab, BB7.2. As shown in Fig. 8C, induction of differentiation dramatically increased the recovery of total A2/C relative to that of HA-A2, as measured by Western blot analysis (compare Fig. 8C, lanes 5 and 6 with Fig. 8B, lanes 8 and 9) without demonstrating a corresponding increase in phosphorylated forms (Fig. 8C, lanes 2 and 3). Thus, these data support our model, that differentiation reduced A2/C phosphorylation, which in turn resulted in stabilization of A2/C protein.
| Discussion |
|---|
|
|
|---|
The influence of the extracellular domain of MHC-I on its surface expression was not surprising. This region of the molecule dictates the peptides MHC-I will bind and ultimately regulates release from the ER and transport to the cell surface. Indeed, the addition of HLA-C-specific peptides has been reported to promote the release of HLA-C from TAP in vitro (29), and thus would be expected to decrease ER retention. Based on these data, it is tempting to speculate that HLA-C expression would increase with a broadening of intracellular peptides such as would occur with infection by viruses or intracellular bacteria. To this end we did examine several viruses (HIV and adenovirus) without detecting any significant change in HLA-C expression. Obviously, however, we cannot rule out the possibility that specific peptides found in other kinds of pathogens might stimulate the release of HLA-C from the ER.
The bigger surprise was the discovery of an internalization and lysosomal targeting signal within the HLA-C cytoplasmic tail. This motif was identified by the demonstration that mutating isoleucine at position 337 to a threonine reversed the phenotype conferred by swapping the HLA-C cytoplasmic tail for the HLA-A2 cytoplasmic tail. Interestingly, the sequence surrounding this residue resembles a Golgi localized,
-ear containing, ARF-binding (GGA) consensus binding motif (DXXLL: reviewed in (30)). GGAs are localized to the TGN and endosomal compartments, and are thought to play a role in trafficking between the TGN and endosomes. Thus, it was possible that GGAs played a role in targeting HLA-C into the endolysosomal pathway from the cell surface or the TGN. However, while we observed some reduction in surface expression and some alteration in intracellular localization with knockdown of GGA-2 and -3, we observed no significant change in the surface transport rate, internalization, recycling or degradation rates. Also, arguing against a role for the GGAs, we found that mutation of the required aspartic acid residue at position 333 (DXSLI) to an alanine, actually increased the activity of the signal. Based on these data, the role of this amino acid was not to provide a GGA binding site, but rather to attenuate the dihydrophobic signal so as to allow some HLA-C to remain on the cell surface. Thus, we have defined a set of amino acids in the HLA-C cytoplasmic tail, which comprise a novel signal that serves to maintain a precise, low level of HLA-C surface expression. Further work will be needed to identify the corresponding trafficking protein that binds it.
Interestingly, the activity of the HLA-C internalization and lysosomal targeting signal also depended on an adjacent serine (DXSLI), which we directly demonstrated was phosphorylated in vivo. Changes in this position increased or decreased internalization and degradation, depending on the substitution that was made. When serine 335 was changed to a glutamic acid residue, which mimicked the negative charge provided by phosphorylation, internalization and degradation occurred rapidly. When phosphorylation was prevented by changing the serine to an alanine, internalization and degradation were inhibited and cell surface expression was increased.
The complex regulation of HLA-C trafficking was puzzling in that HLA-C cell surface expression was kept low while HLA-C intracellular levels remained fairly high. These observations suggested that under most conditions it is beneficial to keep HLA-C expression low to reduce inhibitory signals that might limit immune surveillance, but that there might be some circumstances in which HLA-C might be rapidly up-regulated, either to increase the capacity of the cell to present certain types of Ags, or to turn down an immune response by increasing signaling to KIRs.
To examine whether HLA-C might be specifically up-regulated under some conditions of immune activation, we treated CEM cells with IFNs (
and
) or with chemicals known to activate T cells (PHA and IL-2), without success. Additionally, we infected the cells with viral pathogens such as adenovirus and HIV, again without significant affect. We then turned to APCs, because these cells have unique roles in Ag presentation (e.g., the capacity to present exogenous Ags in association with MHC-I).
We found that undifferentiated primary monocytes and monocytic cell lines expressed low levels of HLA-C, similar to the other cell types we examined. Upon differentiation, however, we observed a reduction in phosphorylation of A2/C, which correlated with a reduction in internalization and degradation and a corresponding up-regulation of HLA-C and molecules bearing the HLA-C cytoplasmic tail. Under the same conditions, the surface expression of HLA-A and HLA-B molecules remained essentially unchanged or was even reduced somewhat. The dependence of this effect on the cytoplasmic tail, which we demonstrated governs post-Golgi trafficking, ruled out the possibility that this was solely due to a change in the peptide loading capacity of the APCs in the ER. Up-regulation of expression with differentiation depended on the serine adjacent to the dihydrophobic motif (DXSLI). When this serine was modified to a glutamic acid, mimicking phosphorylation, low expression and rapid internalization was maintained upon induction of differentiation. When phosphorylation was inhibited by changing the serine to an alanine residue, high surface expression and reduced internalization resulted and was maintained upon induction of differentiation.
These observations, together with the strong evidence that HLA-C plays a crucial role as an inhibitor of NK cell lysis by virtue of its specific binding of KIRs, suggests that HLA-C is up-regulated on macrophages to down-regulate and/or specifically inhibit lysis of cells bearing these receptors. Interestingly, it has recently been demonstrated that CTLs acquire KIRs coincident with acquisition of effector functions (5). Thus, HLA-C may be up-regulated to provide feedback inhibition of CTLs, once they have fully matured. Alternatively, another, perhaps more intriguing possibility is that HLA-C is specifically up-regulated on APCs to protect them from lysis by mature CTLs while they are cross-presenting exogenous Ags to naive CTLs. The capacity to specifically prevent the lysis of cross-presenting APCs would be advantageous in the setting of a chronic infection in which it was necessary to continuously present Ags over an extended period of time. In preserving these cells by such a mechanism, the resulting increased threshold to lysis may inadvertently create a protected reservoir that aids in the persistence of certain organisms. Indeed, there is a long list of persistent pathogens that can be found in macrophages, including HIV, leishmania, brucella, salmonella, herpes viruses, tuberculosis, legionella, plus others (31, 32, 33, 34, 35, 36, 37, 38). Thus, HLA-C may be precisely regulated to balance the need for continued immune activation by APCs presenting Ags against the cost of allowing some pathogens to persist.
| Acknowledgments |
|---|
| Disclosures |
|---|
|
|
|---|
| Footnotes |
|---|
1 This work was supported by National Institutes of Health Grants RO1 AI051198 and AI046998. M.W. was supported by the University of Michigan Cellular and Molecular Biology Training Program. M.R.S. was supported by the University of Michigan Research Training in Experimental Immunology Training Grant and the Herman and Dorothy Miller Award. D.A.K. was supported by an Irvington Institute Fellowship. ![]()
2 Address correspondence and reprint requests to Dr. Kathleen L. Collins, University of Michigan, 3510 Medical Science Research Building I, 1150 West Medical Center Drive, Ann Arbor, MI 48109. E-mail address: klcollin{at}umich.edu ![]()
3 Abbreviations used in this paper: MHC-I, MHC class I; KIR, killer cell Ig-like receptor; HA, hemagglutinin; ER, endoplasmic reticulum; MFI, mean fluorescence intensity; RIPA, radioimmunoprecipitation assay; endo H, endoglycosidase H; IRES, internal ribosome entry site. ![]()
Received for publication July 11, 2007. Accepted for publication April 2, 2008.
| References |
|---|
|
|
|---|
1-domain
helix of HLA-C heavy chains free of β2-microglobulin. Hum. Immunol. 46: 69-81. [Medline]
responsiveness. Tissue Antigens 50: 555-566. [Medline]
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |